Abstract
Mesenchymal Stromal Cells In article number 2200431, Wenjun Yan, Ling Tao, and co-workers report a novel strategy for improving the curative effect of mesenchymal stromal cell (MSC)-based therapy for myocardial infarction that is achieved by bile acid- arnesoid X receptor (FXR) axis activation. FXR overexpression in MSC facilitates the response of MSC to endogenous bile acid signals, thus enhancing the survival and paracrine angiogenesis of MSC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
